Leo V, Lanzetta D, D’Antona D, la Marca A, Morgante G: Hormonal effects of flutamide in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998;83:99–102.
86Caldwell AS, Eid S, Kay CR, Jimenez M, McMahon AC, Desai R, Allan CM, Smith JT, Handelsman DJ, Walters KA: Haplosufficient genomic androgen receptor signaling is adequate to protect female mice from induction of polycystic ovary syndrome features by prenatal hyperandrogenization. Endocrinology 2015;156:1441–1452.
87Caldwell ASL, Edwards MC, Desai R, Jimenez M, Gilchrist RB, Handelsman DJ, Walters KA: Neuroendocrine androgen action is a key extraovarian mediator in the development of polycystic ovary syndrome. Proc Natl Acad Sci U S A 2017;114:E3334–E3343.
88Silva MS, Prescott M, Campbell RE: Ontogeny and reversal of brain circuit abnormalities in a preclinical model of PCOS. JCI Insight 2018;3:pii:99405.
89Allen DB: Hormonal eligibility criteria for ‘includes females’ competition: a practical but problematic solution. Horm Res Paediatr 2016;85:278–282.
90Batty KA, Herbert J, Keverne EB, Vellucci SV: Differences in blood levels of androgens in female talapoin monkeys related to their social status. Neuroendocrinology 1986;44:347–354.
91Petty JM, Drea CM: Female rule in lemurs is ancestral and hormonally mediated. Sci Rep 2015;5:9631.
92Azziz R, Sanchez LA, Knochenhauer ES, Moran C, Lazenby J, Stephens KC, Taylor K, Boots LR: Androgen excess in women: experience with over 1,000 consecutive patients. J Clin Endocrinol Metab 2004;89:453–462.
93Arifin E, Shively CA, Register TC, Cline JM: Polycystic ovary syndrome with endometrial hyperplasia in a cynomolgus monkey (Macaca fascicularis). Vet Pathol 2008;45:512–515.
94Abbott DH, Rayome BH, Dumesic DA, Lewis KC, Edwards AK, Wallen K, Wilson ME, Appt SE, Levine JE: Clustering of PCOS-like traits in naturally hyperandrogenic female rhesus monkeys. Hum Reprod 2017;32:923–936.
95Foong SC, Abbott DH, Zschunke MA, Lesnick TG, Phy JL, Dumesic DA: Follicle luteinization in hyperandrogenic follicles of polycystic ovary syndrome patients undergoing gonadotropin therapy for in vitro fertilization. J Clin Endocrinol Metab 2006;91:2327–2333.
96Azziz R, Dumesic DA, Goodarzi MO: Polycystic ovary syndrome: an ancient disorder? Fertil Steril 2011;95:1544–1548.
David H. Abbott, PhD
Department of Ob/Gyn and Wisconsin National Primate Research Center, University of Wisconsin
1223 Capitol Court
Madison, WI 53711 (USA)
E-Mail [email protected]
Pasquali R, Pignatelli D (eds): Hyperandrogenism in Women. Beyond Polycystic Ovary Syndrome.
Front Horm Res. Basel, Karger, 2019, vol 53, pp 18–32 (DOI: 10.1159/000494900)
______________________
Androgens, Body Composition, and Their Metabolism Based on Sex
Vito Angelo Giagullia Marco Castellanab Carla Pelusic Vincenzo Triggiania
aSection of Internal Medicine, Geriatrics, Endocrinology and Rare Diseases, Interdisciplinary Department of Medicine, University of Bari, School of Medicine, Policlinico, Bari, Italy; bRutigliano, Bari, Italy; cDivision of Endocrinology and Center for Applied Biomedical Research, Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy
______________________
Abstract
Differences between males and females are commonly attributed to sexual hormones. Androgens are responsible for the development of primary and secondary sexual characteristics in males, whereas they influence sexual behaviour, glycaemic control, lipid profile, bone metabolism and erythropoiesis in both sexes. In this chapter, we discuss preclinical and clinical data on sex-specific androgen metabolism and androgen effect on body composition.
© 2019 S. Karger AG, Basel
Introduction
Androgens encompass several steroid hormones that may be de novo secreted by gonads and adrenal glands or produced in different tissues from circulating precursors. According to their natural ability to bind the androgen receptor (AR), they can be classified into 2 subgroups: the true androgens (active ones), represented by testosterone (T) and its 5α-reduced metabolite dihydrotestosterone (DHT), and pro-androgens (weak ones), including dehydroepiandrosterone, dehydroepiandrosterone-sulphate and androstenedione (A), which begin to be active as far as converted into T and DHT. Recently, it has been pointed out that the major weak androgen is 11β-hydroxyandrostenedione, which is synthetized by the adrenal glands and can be converted both into 11β-hydroxytestosterone and, thereafter, into 11β-hydroxydihydrotestosterone by the 5α-reductase in target tissues; these last 2 androgens bind the AR as well, although being less active than T and DHT [1].
The synthesis of androgens in the gonads is regulated by the luteinizing hormone (LH), secreted by the pituitary gland upon the hypothalamic action of the gonadotropin-releasing hormone (GnRH). Indeed, LH acts on Leydig cells in males and theca cells in females via the steroidogenic acute regulatory protein, promoting the transfer of cholesterol to the inner mitochondrial membrane. Despite common pathways, androgens show sex-dependent features. In males, testes synthesize T, which is converted into DHT in target tissues, such as prostate and seminal vesicles. In females, ovaries synthesize about the half of the circulating T and smaller quantities of dehydroepiandrosterone and A; the remaining T is produced from the conversion of circulating weak androgens (mainly from A). The secretion of adrenal androgens is commonly regarded as being LH-independent and is predominantly characterized by the synthesis of weak androgens in both sexes.
Given that AR is present, hormones can exert their effect in the vicinity of the secreting gland or enter the blood stream. In both sexes, A and T can be converted into oestrogens by aromatase in different tissues, including visceral adipose tissue (VAT). The principal end-metabolites of androgens is androsterone glucuronide (ADTG) and 5α-androstane-3α,17β-diol glucuronide (ADG), produced mainly in splanchnic tissues (gut and liver) rather than in peripheral ones (skin and male internal genitalia). Extra-gonadal metabolic pathways are not influenced by LH but are modulated either by the characteristics of local enzymatic pathways and their co-regulators (i.e., IGF-1) or by the type and quantity of androgens locally present [2, 3].
In males, androgens are responsible for the development of primary and secondary sexual characteristics, whereas in both sexes, they influence